Subcutaneous GIP and GLP-2 inhibit nightly bone resorption in postmenopausal women: A preliminary study
Research output: Contribution to journal › Journal article › Research › peer-review
Standard
Subcutaneous GIP and GLP-2 inhibit nightly bone resorption in postmenopausal women : A preliminary study. / Skov-Jeppesen, Kirsa; Veedfald, Simon; Madsbad, Sten; Holst, Jens Juul; Rosenkilde, Mette Marie; Hartmann, Bolette.
In: Bone, Vol. 152, 116065, 2021.Research output: Contribution to journal › Journal article › Research › peer-review
Harvard
APA
Vancouver
Author
Bibtex
}
RIS
TY - JOUR
T1 - Subcutaneous GIP and GLP-2 inhibit nightly bone resorption in postmenopausal women
T2 - A preliminary study
AU - Skov-Jeppesen, Kirsa
AU - Veedfald, Simon
AU - Madsbad, Sten
AU - Holst, Jens Juul
AU - Rosenkilde, Mette Marie
AU - Hartmann, Bolette
N1 - Copyright © 2021 The Authors. Published by Elsevier Inc. All rights reserved.
PY - 2021
Y1 - 2021
N2 - BACKGROUND: Glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-2 (GLP-2) are gut hormones secreted in response to food ingestion, and they have been suggested to regulate bone turnover. In humans, exogenous GIP and GLP-2 acutely inhibit bone resorption as measured by circulating levels of carboxy-terminal type 1 collagen crosslinks (CTX).OBJECTIVE: The objective was to study the individual and combined acute effects of GIP and GLP-2 on bone turnover in postmenopausal women during nighttime - a period of increased bone resorption.METHODS: Using a randomized, placebo-controlled, double-blinded, crossover design, each participant (n = 9) received on four separate study days: GIP, GLP-2, GIP + GLP-2, and placebo (saline) as subcutaneous injections at bedtime. Main outcomes were levels of CTX and procollagen type 1 N-terminal propeptide (P1NP).RESULTS: Compared with placebo, GIP and GLP-2 alone significantly inhibited bone resorption (measured by CTX). GIP rapidly reduced CTX levels in the period from 45 to 120 min after injection, while GLP-2 had a more delayed effect with reduced CTX levels in the period from 120 to 240 min after injection. Combining GIP and GLP-2 showed complementary effects resulting in a sustained inhibition of CTX with reduced levels from 45 to 240 min after injection. Furthermore, GIP acutely increased bone formation (measured by P1NP).CONCLUSION: Both GIP and GLP-2 reduced CTX during the night and had complementary effects when combined.
AB - BACKGROUND: Glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-2 (GLP-2) are gut hormones secreted in response to food ingestion, and they have been suggested to regulate bone turnover. In humans, exogenous GIP and GLP-2 acutely inhibit bone resorption as measured by circulating levels of carboxy-terminal type 1 collagen crosslinks (CTX).OBJECTIVE: The objective was to study the individual and combined acute effects of GIP and GLP-2 on bone turnover in postmenopausal women during nighttime - a period of increased bone resorption.METHODS: Using a randomized, placebo-controlled, double-blinded, crossover design, each participant (n = 9) received on four separate study days: GIP, GLP-2, GIP + GLP-2, and placebo (saline) as subcutaneous injections at bedtime. Main outcomes were levels of CTX and procollagen type 1 N-terminal propeptide (P1NP).RESULTS: Compared with placebo, GIP and GLP-2 alone significantly inhibited bone resorption (measured by CTX). GIP rapidly reduced CTX levels in the period from 45 to 120 min after injection, while GLP-2 had a more delayed effect with reduced CTX levels in the period from 120 to 240 min after injection. Combining GIP and GLP-2 showed complementary effects resulting in a sustained inhibition of CTX with reduced levels from 45 to 240 min after injection. Furthermore, GIP acutely increased bone formation (measured by P1NP).CONCLUSION: Both GIP and GLP-2 reduced CTX during the night and had complementary effects when combined.
U2 - 10.1016/j.bone.2021.116065
DO - 10.1016/j.bone.2021.116065
M3 - Journal article
C2 - 34153529
VL - 152
JO - Bone
JF - Bone
SN - 8756-3282
M1 - 116065
ER -
ID: 275886501